Published in Cell on February 19, 2010
The hippo signaling pathway in development and cancer. Dev Cell (2010) 10.54
The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell (2010) 4.47
The FERM domain: organizing the structure and function of FAK. Nat Rev Mol Cell Biol (2010) 2.23
Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell (2013) 2.16
A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions. Cancer Cell (2011) 1.86
The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy. Genes Cancer (2010) 1.80
Comparative RNAi screening identifies a conserved core metazoan actinome by phenotype. J Cell Biol (2011) 1.75
Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria. Am J Med Genet A (2013) 1.72
Mst1/2 signalling to Yap: gatekeeper for liver size and tumour development. Br J Cancer (2010) 1.53
Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus. EMBO Rep (2012) 1.30
Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A (2011) 1.24
Regulation of G protein-coupled receptor function by Na+/H+ exchange regulatory factors. Pharmacol Rev (2011) 1.22
Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus. Cancer Cell (2014) 1.22
Regulation of Drosophila glial cell proliferation by Merlin-Hippo signaling. Development (2011) 1.19
Cullins and cancer. Genes Cancer (2010) 1.16
MicroRNA-107, an oncogene microRNA that regulates tumour invasion and metastasis by targeting DICER1 in gastric cancer. J Cell Mol Med (2011) 1.15
Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS One (2012) 1.13
Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase. Nat Commun (2013) 1.12
Angiomotin binding-induced activation of Merlin/NF2 in the Hippo pathway. Cell Res (2015) 1.09
Pathogenic Role of the CRL4 Ubiquitin Ligase in Human Disease. Front Oncol (2012) 1.08
Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms. Acta Neuropathol (2011) 1.04
Bromodomain protein 7 interacts with PRMT5 and PRC2, and is involved in transcriptional repression of their target genes. Nucleic Acids Res (2011) 1.03
New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment. Clin Cancer Res (2012) 1.03
Molecular insights into NF2/Merlin tumor suppressor function. FEBS Lett (2014) 1.03
Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways. Neoplasia (2011) 1.02
Proteomic profiling of the human cytomegalovirus UL35 gene products reveals a role for UL35 in the DNA repair response. J Virol (2011) 1.01
Tissue repair through cell competition and compensatory cellular hypertrophy in postmitotic epithelia. Dev Cell (2013) 1.00
Microtubule-mediated transport of the tumor-suppressor protein Merlin and its mutants. Proc Natl Acad Sci U S A (2010) 0.98
Rac1 controls Schwann cell myelination through cAMP and NF2/merlin. J Neurosci (2012) 0.94
VprBP has intrinsic kinase activity targeting histone H2A and represses gene transcription. Mol Cell (2013) 0.94
Vpr-binding protein antagonizes p53-mediated transcription via direct interaction with H3 tail. Mol Cell Biol (2011) 0.94
Cell competition and its implications for development and cancer. J Genet Genomics (2011) 0.94
CRL4-DDB1-VPRBP ubiquitin ligase mediates the stress triggered proteolysis of Mcm10. Nucleic Acids Res (2012) 0.93
Netrin-4 promotes glioblastoma cell proliferation through integrin β4 signaling. Neoplasia (2012) 0.93
The molecular biology of vestibular schwannomas and its association with hearing loss: a review. Genet Res Int (2012) 0.90
Compensatory cellular hypertrophy: the other strategy for tissue homeostasis. Trends Cell Biol (2013) 0.89
NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations. Oncotarget (2014) 0.89
VprBP (DCAF1): a promiscuous substrate recognition subunit that incorporates into both RING-family CRL4 and HECT-family EDD/UBR5 E3 ubiquitin ligases. BMC Mol Biol (2013) 0.88
Cellular Organization and Cytoskeletal Regulation of the Hippo Signaling Network. Trends Cell Biol (2016) 0.88
Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future. Ann Cardiothorac Surg (2012) 0.87
Control of Proliferation and Cancer Growth by the Hippo Signaling Pathway. Mol Cancer Res (2015) 0.87
Contribution of persistent C-Jun N-terminal kinase activity to the survival of human vestibular schwannoma cells by suppression of accumulation of mitochondrial superoxides. Neuro Oncol (2011) 0.87
Hippo/YAP pathway for targeted therapy. Transl Lung Cancer Res (2014) 0.87
Deregulation of cell signaling in cancer. FEBS Lett (2014) 0.87
NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition. Cancer Discov (2015) 0.86
Neurofibromatosis-related tumors: emerging biology and therapies. Curr Opin Pediatr (2015) 0.85
Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas. Neuro Oncol (2014) 0.85
Role of Merlin/NF2 inactivation in tumor biology. Oncogene (2015) 0.85
Transcriptional regulation of serine/threonine protein kinase (AKT) genes by glioma-associated oncogene homolog 1. J Biol Chem (2013) 0.85
Back to the future: proceedings from the 2010 NF Conference. Am J Med Genet A (2010) 0.84
VprBP binds full-length RAG1 and is required for B-cell development and V(D)J recombination fidelity. EMBO J (2011) 0.84
Therapeutic potential of HSP90 inhibition for neurofibromatosis type 2. Clin Cancer Res (2013) 0.84
FERM domain phosphoinositide binding targets merlin to the membrane and is essential for its growth-suppressive function. Mol Cell Biol (2011) 0.84
Neurofibromatosis type 2 tumor suppressor protein, NF2, induces proteasome-mediated degradation of JC virus T-antigen in human glioblastoma. PLoS One (2013) 0.84
Microarray analysis of gene expression in vestibular schwannomas reveals SPP1/MET signaling pathway and androgen receptor deregulation. Int J Oncol (2013) 0.84
Hippo transducer TAZ promotes epithelial mesenchymal transition and supports pancreatic cancer progression. Oncotarget (2015) 0.84
DCAF1 controls T-cell function via p53-dependent and -independent mechanisms. Nat Commun (2016) 0.83
p75NTR is highly expressed in vestibular schwannomas and promotes cell survival by activating nuclear transcription factor κB. Glia (2014) 0.83
A neuronal function of the tumor suppressor protein merlin. Acta Neuropathol Commun (2014) 0.83
The NF2 tumor suppressor regulates microtubule-based vesicle trafficking via a novel Rac, MLK and p38(SAPK) pathway. Oncogene (2012) 0.83
Neurofibromatosis 2011: a report of the Children's Tumor Foundation annual meeting. Acta Neuropathol (2011) 0.83
NF2 Activates Hippo Signaling and Promotes Ischemia/Reperfusion Injury in the Heart. Circ Res (2016) 0.82
Tumor suppressor NF2/Merlin is a microtubule stabilizer. Cancer Res (2013) 0.81
Global profiling in vestibular schwannomas shows critical deregulation of microRNAs and upregulation in those included in chromosomal region 14q32. PLoS One (2013) 0.81
Defining the interactions and role of DCAF1/VPRBP in the DDB1-cullin4A E3 ubiquitin ligase complex engaged by HIV-1 Vpr to induce a G2 cell cycle arrest. PLoS One (2014) 0.81
CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies. Am J Med Genet A (2014) 0.81
Multistep phosphorylation by oncogenic kinases enhances the degradation of the NF2 tumor suppressor merlin. Neoplasia (2011) 0.81
Merlin's tumor suppression linked to inhibition of the E3 ubiquitin ligase CRL4 (DCAF1). Cell Cycle (2010) 0.81
Important recent insights into the genetics and biology of malignant pleural mesothelioma. Ann Cardiothorac Surg (2012) 0.81
Merlin status regulates p75(NTR) expression and apoptotic signaling in Schwann cells following nerve injury. Neurobiol Dis (2015) 0.81
Structural basis of the binding of Merlin FERM domain to the E3 ubiquitin ligase substrate adaptor DCAF1. J Biol Chem (2014) 0.81
Distinct overlapping sequences at the carboxy-terminus of merlin regulate its tumour suppressor and morphogenic activity. J Cell Mol Med (2012) 0.80
The role and mechanism of CRL4 E3 ubiquitin ligase in cancer and its potential therapy implications. Oncotarget (2015) 0.80
Role of Angiomotin-like 2 mono-ubiquitination on YAP inhibition. EMBO Rep (2015) 0.80
Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies. Acta Otorhinolaryngol Ital (2016) 0.79
Distinct and overlapping functions of the cullin E3 ligase scaffolding proteins CUL4A and CUL4B. Gene (2015) 0.79
The hippo tumor suppressor network: from organ size control to stem cells and cancer. Cancer Res (2013) 0.79
Loss of SOX10 function contributes to the phenotype of human Merlin-null schwannoma cells. Brain (2013) 0.79
Merlin/NF2 Suppresses Pancreatic Tumor Growth and Metastasis by Attenuating the FOXM1-Mediated Wnt/β-Catenin Signaling. Cancer Res (2015) 0.79
Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study. J Mol Biol (2014) 0.79
Schwann cells induce cancer cell dispersion and invasion. J Clin Invest (2016) 0.78
Methylation of histone H4 at aspartate 24 by protein L-isoaspartate O-methyltransferase (PCMT1) links histone modifications with protein homeostasis. Sci Rep (2014) 0.78
Stability of the tumor suppressor merlin depends on its ability to bind paxillin LD3 and associate with β1 integrin and actin at the plasma membrane. Biol Open (2012) 0.78
Update from the 2013 International Neurofibromatosis Conference. Am J Med Genet A (2014) 0.78
Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. Nat Commun (2016) 0.77
DNA copy gains of tumor-related genes in vestibular schwannoma. Eur Arch Otorhinolaryngol (2012) 0.77
The biomolecular era for thoracic surgeons: the example of the ESTS Biology Club. J Thorac Dis (2014) 0.77
The Emerging Role of TRAF7 in Tumor Development. J Cell Physiol (2016) 0.77
Oncogenic role of Merlin/NF2 in glioblastoma. Oncogene (2014) 0.77
YAP Mediates Tumorigenesis in Neurofibromatosis Type 2 by Promoting Cell Survival and Proliferation through a COX-2-EGFR Signaling Axis. Cancer Res (2016) 0.76
Neurofibromatosis type 2 protein, NF2: an uncoventional cell cycle regulator. Anticancer Res (2013) 0.76
The hippo signaling pathway: implications for heart regeneration and disease. Clin Transl Med (2014) 0.76
Regulation of localization and function of the transcriptional co-activator YAP by angiomotin. Elife (2017) 0.75
Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target. EBioMedicine (2017) 0.75
Protein 4.1R Influences Myogenin Protein Stability and Skeletal Muscle Differentiation. J Biol Chem (2016) 0.75
Cep78 controls centrosome homeostasis by inhibiting EDD-DYRK2-DDB1(Vpr)(BP). EMBO Rep (2017) 0.75
Merlin inhibits Wnt/β-catenin signaling by blocking LRP6 phosphorylation. Cell Death Differ (2016) 0.75
The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors. Oncogene (2015) 0.75
Tumor suppressor protein Lgl mediates G1 cell cycle arrest at high cell density by forming an Lgl-VprBP-DDB1 complex. Mol Biol Cell (2015) 0.75
Cancer: a new role for non-canonical Hippo signaling. Cell Res (2017) 0.75
Wnt/beta-catenin signaling in development and disease. Cell (2006) 30.09
ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol (2002) 8.41
The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol (2005) 6.74
Hippo signaling in organ size control. Genes Dev (2007) 6.29
A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1. Mol Cell (2006) 5.51
Delineation of a Fat tumor suppressor pathway. Nat Genet (2006) 5.06
Membrane organization and tumorigenesis--the NF2 tumor suppressor, Merlin. Genes Dev (2005) 3.59
Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. Mol Cell (2008) 3.31
Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol Cell Biol (2009) 3.25
Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J Cell Biol (2007) 2.89
The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell (2001) 2.89
CUL4A abrogation augments DNA damage response and protection against skin carcinogenesis. Mol Cell (2009) 2.79
DCAFs, the missing link of the CUL4-DDB1 ubiquitin ligase. Mol Cell (2007) 2.72
Lentiviral Vpr usurps Cul4-DDB1[VprBP] E3 ubiquitin ligase to modulate cell cycle. Proc Natl Acad Sci U S A (2007) 2.64
NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev (2003) 2.55
Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol Cell (2003) 2.23
Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase. Nature (2006) 2.15
p21-activated kinase links Rac/Cdc42 signaling to merlin. J Biol Chem (2001) 2.05
Ubiquitin proteasome system (UPS): what can chromatin do for you? Curr Opin Cell Biol (2007) 1.90
Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane. J Cell Biol (2005) 1.86
Shedding light on Merlin's wizardry. Trends Cell Biol (2007) 1.85
Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. J Biol Chem (2002) 1.82
Protein kinase DYRK2 is a scaffold that facilitates assembly of an E3 ligase. Nat Cell Biol (2009) 1.79
NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol (2009) 1.78
Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas. Oncogene (2008) 1.57
Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma. Cancer Res (2008) 1.55
Merlin and the ERM proteins--regulators of receptor distribution and signaling at the cell cortex. Trends Cell Biol (2009) 1.54
Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells. Hum Mol Genet (2003) 1.47
VprBP targets Merlin to the Roc1-Cul4A-DDB1 E3 ligase complex for degradation. Oncogene (2008) 1.44
Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene (2006) 1.38
Human immunodeficiency virus type 1 Vpr-binding protein VprBP, a WD40 protein associated with the DDB1-CUL4 E3 ubiquitin ligase, is essential for DNA replication and embryonic development. Mol Cell Biol (2008) 1.36
Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. Proc Natl Acad Sci U S A (2004) 1.34
Breast cancer antiestrogen resistance-3 expression regulates breast cancer cell migration through promotion of p130Cas membrane localization and membrane ruffling. Cancer Res (2007) 1.33
Akt phosphorylation regulates the tumour-suppressor merlin through ubiquitination and degradation. Nat Cell Biol (2007) 1.31
Structural basis for neurofibromatosis type 2. Crystal structure of the merlin FERM domain. J Biol Chem (2001) 1.30
Mutational spectrum of the NF2 gene: a meta-analysis of 12 years of research and diagnostic laboratory findings. Hum Mutat (2007) 1.21
Cell cycle-dependent nucleocytoplasmic shuttling of the neurofibromatosis 2 tumour suppressor merlin. Oncogene (2005) 0.99
An alternative domain determines nuclear localization in multifunctional protein 4.1. J Biol Chem (1998) 0.97
Functional analysis of neurofibromatosis 2 (NF2) missense mutations. Hum Mol Genet (2001) 0.94
Nucleocytoplasmic transfer of the NF2 tumor suppressor protein merlin is regulated by exon 2 and a CRM1-dependent nuclear export signal in exon 15. Hum Mol Genet (2002) 0.88
Deciphering the nuclear import pathway for the cytoskeletal red cell protein 4.1R. Mol Biol Cell (1999) 0.86
Analysis of integrin signaling in genetically engineered mouse models of mammary tumor progression. Methods Enzymol (2007) 0.82
Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science (2002) 24.31
mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell (2002) 18.22
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol (2004) 16.83
Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev (2002) 13.08
PRDM16 controls a brown fat/skeletal muscle switch. Nature (2008) 13.08
DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature (2007) 11.14
Histone demethylation by a family of JmjC domain-containing proteins. Nature (2005) 10.36
Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol (2009) 9.67
Role of histone H2A ubiquitination in Polycomb silencing. Nature (2004) 9.48
Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell (2005) 7.75
Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription. Nature (2008) 7.18
Integrin signalling during tumour progression. Nat Rev Mol Cell Biol (2004) 6.53
Recognition of trimethylated histone H3 lysine 4 facilitates the recruitment of transcription postinitiation factors and pre-mRNA splicing. Mol Cell (2007) 5.78
Regulation of p53 activity through lysine methylation. Nature (2004) 5.78
Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell (2007) 5.62
PR-Set7 is a nucleosome-specific methyltransferase that modifies lysine 20 of histone H4 and is associated with silent chromatin. Mol Cell (2002) 5.59
JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor. Cell (2006) 5.54
Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr Biol (2002) 5.53
The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36. Nature (2006) 5.51
Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature (2010) 5.47
Set9, a novel histone H3 methyltransferase that facilitates transcription by precluding histone tail modifications required for heterochromatin formation. Genes Dev (2002) 5.43
Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol Cell (2004) 5.37
GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell (2003) 5.21
NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell (2007) 5.20
Histone deimination antagonizes arginine methylation. Cell (2004) 5.19
Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet (2008) 5.07
Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3. Mol Cell (2004) 5.06
Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell (2006) 4.48
The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell (2010) 4.47
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
TLR signalling augments macrophage bactericidal activity through mitochondrial ROS. Nature (2011) 4.16
Purification and functional characterization of SET8, a nucleosomal histone H4-lysine 20-specific methyltransferase. Curr Biol (2002) 4.12
Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell (2002) 4.08
Lysine methylation within the globular domain of histone H3 by Dot1 is important for telomeric silencing and Sir protein association. Genes Dev (2002) 4.07
Monoubiquitination of human histone H2B: the factors involved and their roles in HOX gene regulation. Mol Cell (2005) 4.04
Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol Cell Biol (2004) 3.90
Regulation of the brown and white fat gene programs through a PRDM16/CtBP transcriptional complex. Genes Dev (2008) 3.90
P-Rex1, a PtdIns(3,4,5)P3- and Gbetagamma-regulated guanine-nucleotide exchange factor for Rac. Cell (2002) 3.80
The retinoblastoma binding protein RBP2 is an H3K4 demethylase. Cell (2007) 3.79
Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev (2010) 3.77
Siah2 regulates stability of prolyl-hydroxylases, controls HIF1alpha abundance, and modulates physiological responses to hypoxia. Cell (2004) 3.77
L3MBTL1, a histone-methylation-dependent chromatin lock. Cell (2007) 3.70
PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol Cell (2007) 3.68
Genomic analysis of reactive astrogliosis. J Neurosci (2012) 3.62
Membrane organization and tumorigenesis--the NF2 tumor suppressor, Merlin. Genes Dev (2005) 3.59
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol (2009) 3.48
Histone H3 and H4 ubiquitylation by the CUL4-DDB-ROC1 ubiquitin ligase facilitates cellular response to DNA damage. Mol Cell (2006) 3.39
An iron delivery pathway mediated by a lipocalin. Mol Cell (2002) 3.38
Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway. Cell (2006) 3.31
Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol Cell Biol (2009) 3.25
Wnt/beta-catenin signaling is required for CNS, but not non-CNS, angiogenesis. Proc Natl Acad Sci U S A (2009) 3.17
The core of the polycomb repressive complex is compositionally and functionally conserved in flies and humans. Mol Cell Biol (2002) 3.13
Repeatability and reproducibility in proteomic identifications by liquid chromatography-tandem mass spectrometry. J Proteome Res (2010) 3.08
mAM facilitates conversion by ESET of dimethyl to trimethyl lysine 9 of histone H3 to cause transcriptional repression. Mol Cell (2003) 2.97
A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell (2006) 2.95
A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res (2012) 2.95
Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat Cell Biol (2009) 2.91
WSTF regulates the H2A.X DNA damage response via a novel tyrosine kinase activity. Nature (2008) 2.86
The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell (2012) 2.84